First Header Logo Second Header Logo

Connection

Pierre Triozzi to Male

Back to Details
This is a "connection" page, showing publications Pierre Triozzi has written about Male.
Pierre Triozzi
Connection Strength
0.546
Male
  1. Triozzi PL, Achberger S, Aldrich W, Crabb JW, Saunthararajah Y, Singh AD. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. Clin Epigenetics. 2016; 8:80.
    View in: PubMed
    Score: 0.040
  2. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016 Apr; 100(4):456-62.
    View in: PubMed
    Score: 0.037
  3. Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 2014 Apr; 58(2):182-6.
    View in: PubMed
    Score: 0.033
  4. Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL. Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 15; 19(14):3996-4007.
    View in: PubMed
    Score: 0.032
  5. Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD. Elevated blood ß-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013 Feb; 23(1):1-7.
    View in: PubMed
    Score: 0.031
  6. Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012 Sep; 35(7):587-94.
    View in: PubMed
    Score: 0.030
  7. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer. 2012 Jul 01; 131(1):18-29.
    View in: PubMed
    Score: 0.028
  8. Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011 Jul 25; 52(8):5529-35.
    View in: PubMed
    Score: 0.028
  9. Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon ß in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011 May; 31(5):433-40.
    View in: PubMed
    Score: 0.027
  10. Triozzi PL, Singh AD. Blood biomarkers of uveal melanoma metastasis. Br J Ophthalmol. 2011 Jan; 95(1):3-4.
    View in: PubMed
    Score: 0.027
  11. Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. Prostate. 2005 Dec 01; 65(4):316-21.
    View in: PubMed
    Score: 0.019
  12. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother. 2005 Jul-Aug; 28(4):382-8.
    View in: PubMed
    Score: 0.018
  13. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 2005 Jun 01; 11(11):4168-75.
    View in: PubMed
    Score: 0.018
  14. Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther. 2005 Jan; 16(1):91-100.
    View in: PubMed
    Score: 0.018
  15. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res. 2002 Jul; 8(7):2044-51.
    View in: PubMed
    Score: 0.015
  16. Helis CA, Hughes RT, Glenn CW, Lanier CM, Masters AH, Dohm A, Ahmed T, Ruiz J, Triozzi P, Gondal H, Cramer CK, Tatter SB, Laxton AW, Xing F, Lo HW, Su J, Watabe K, Wang G, Whitlow CT, Chan MD. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):295-303.
    View in: PubMed
    Score: 0.013
  17. Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 10 07; 9(1):14385.
    View in: PubMed
    Score: 0.012
  18. Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes. Br J Ophthalmol. 2020 04; 104(4):524-528.
    View in: PubMed
    Score: 0.012
  19. Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas TJ, Morse DL. Melanocortin 1 Receptor-Targeted a-Particle Therapy for Metastatic Uveal Melanoma. J Nucl Med. 2019 08; 60(8):1124-1133.
    View in: PubMed
    Score: 0.012
  20. Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 02; 28(1):44-51.
    View in: PubMed
    Score: 0.011
  21. Schuermeyer I, Maican A, Sharp R, Bena J, Triozzi PL, Singh AD. Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis. JAMA Ophthalmol. 2016 Jan; 134(1):51-6.
    View in: PubMed
    Score: 0.010
  22. Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD. iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. PLoS One. 2015; 10(8):e0135543.
    View in: PubMed
    Score: 0.009
  23. Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. . 2014 Aug; 15(8):975-81.
    View in: PubMed
    Score: 0.009
  24. Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol. 2014 Jan; 32(1):33.e11-7.
    View in: PubMed
    Score: 0.008
  25. Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012 Jun 05; 53(7):3331-9.
    View in: PubMed
    Score: 0.007
  26. Yi T, Elson P, Mitsuhashi M, Jacobs B, Hollovary E, Budd TG, Spiro T, Triozzi P, Borden EC. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget. 2011 Dec; 2(12):1155-64.
    View in: PubMed
    Score: 0.007
  27. Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI. Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol. 2011 Aug; 31(4):690-8.
    View in: PubMed
    Score: 0.007
  28. Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU Int. 2011 Feb; 107(4):562-70.
    View in: PubMed
    Score: 0.007
  29. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6277-83.
    View in: PubMed
    Score: 0.006
  30. Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008 May 15; 14(10):3052-9.
    View in: PubMed
    Score: 0.006
  31. Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, Fujimori M, Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm. 2006 Dec; 21(6):561-8.
    View in: PubMed
    Score: 0.005
  32. Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine. 2004 Jan 26; 22(5-6):773-80.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.